Fibromyalgia is one of the more difficult conditions to treat, partly because it doesn’t show up cleanly on a scan or a blood test. Chronic widespread pain, fatigue, tender points and brain fog can be very real and very disruptive, even when standard diagnostics look unremarkable.
That combination has led researchers to explore a range of interventions, including hyperbaric oxygen therapy (HBOT). The results are genuinely interesting — and genuinely mixed, which is exactly why they deserve an honest look rather than a marketing pitch.
At Core iV Therapy®, we’d rather walk you through what the research actually found than oversell what our 1.3 ATA mild hyperbaric chamber can do for fibromyalgia symptoms.

What the Research Found
A 2023 meta-analysis pooled four randomized controlled trials involving 163 participants with fibromyalgia. It found improvements in fibromyalgia-impact measures and tender-point counts among people who received HBOT.
But here’s the part that’s easy to skip if you only read the headline: pain improvement itself was not statistically significant across the pooled trials, and side effects were reported more frequently in the HBOT groups than in controls.
In three words: promising, interesting, not magic.
Why This Matters for How We Talk About It
Fibromyalgia is a condition where people have often already tried multiple treatments with disappointing results. That makes honest expectation-setting especially important. We won’t tell someone HBOT will resolve their pain — the pooled data doesn’t support that specific claim.
What we can say is that the broader impact measures and tender-point findings are worth taking seriously as an area of ongoing investigation, and that hyperbaric oxygen may be a reasonable therapy to explore as part of a broader, individualized approach — not a stand-alone fix.
How We Approach Sessions
Our mild hyperbaric chamber operates at approximately 1.3 ATA — a pressure chosen for tolerability, which matters given that the research noted more frequent side effects with HBOT than with sham treatment. Sessions include supplemental oxygen delivery by mask when appropriate, and we build protocols around repeated, individualized sessions rather than a single visit, consistent with how the supportive studies were structured.

What This Looks Like at Core iV
For clients with fibromyalgia exploring HBOT, we typically emphasize:
- A conservative, individualized approach given the higher reported side-effect rate
- Sessions of roughly 60 minutes at therapeutic pressure
- Supplemental oxygen delivery by mask
- Realistic framing — supportive for impact measures, not a proven pain cure
Talk to Us About Your Symptoms
You can also read a broader overview of the complementary therapies we offer for fibromyalgia — including IV nutrient therapy, ozone, and mHBOT — on our Fibromyalgia Support page.
If you’re living with fibromyalgia and wondering whether hyperbaric oxygen belongs in your care plan, schedule a consultation with Core iV Therapy®. We’ll talk through your symptoms, your history and what a realistic protocol could look like.
Core IV Therapy® is located at 108 Elden Street, Suite 15A, Herndon, VA 20170. Call 866-426-7348 or book online.
Quick Answers
Does hyperbaric oxygen therapy help fibromyalgia?
A 2023 meta-analysis of four randomized trials (163 participants) found improvements in fibromyalgia-impact measures and tender-point counts, but pain improvement itself was not statistically significant across the pooled data.
Are there side effects to HBOT for fibromyalgia?
The 2023 meta-analysis reported side effects more frequently in HBOT groups than in control groups, which is part of why we recommend a conservative, individualized approach.
Is hyperbaric oxygen a cure for fibromyalgia pain?
No. The research does not support that claim. It’s best considered an area of ongoing investigation that may support certain impact measures, not a proven pain treatment.
What pressure does Core iV Therapy use for fibromyalgia support?
Our mild hyperbaric chamber operates at approximately 1.3 ATA with supplemental oxygen delivery by mask, chosen for tolerability and repeatable, individualized use.
Reference
Cao et al. 2023 – Fibromyalgia
Meta-analysis of randomized controlled trials evaluating HBOT in fibromyalgia.